Off-Label Photodynamic Therapy Coverage Extended To AMD Population
This article was originally published in The Gray Sheet
Executive Summary
Clinical trial subgroup analyses showing the ability of lesion size to predict patient benefit helped convince CMS to expand national Medicare coverage of QLT/Novartis' Visudyne (verteporfin)
You may also be interested in...
MCAC To Weigh Emerging Treatments For Age-Related Macular Degeneration
CMS' Medicare Coverage Advisory Committee will convene Nov. 29 in Baltimore to evaluate the evidence for age-related macular degeneration (AMD) treatments
MCAC To Weigh Emerging Treatments For Age-Related Macular Degeneration
CMS' Medicare Coverage Advisory Committee will convene Nov. 29 in Baltimore to evaluate the evidence for age-related macular degeneration (AMD) treatments
MCAC on age-related macular degeneration
CMS' Medicare Coverage Advisory Committee will convene Nov. 29 in Baltimore to discuss age-related macular degeneration treatments. In 2004, the agency approved coverage for photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) in patients who have occult and minimally classic lesions (1"The Gray Sheet" Feb. 2, 2004, p. 16). Alcon, Miravant Medical Technologies and Occulogix are also developing age-related macular degeneration products...